2Morrow’s CEO, Brandon Masterson, Sits Down with Portland Seed Fund to Discuss the Current State of Digital Therapeutics.

Brandon explains:

"We’re in an exciting time in the digital therapeutics space, because it’s early days in the industry for measuring the results of behavior programs and having clinical evidence at a level that’s on par with medical devices and pharmaceutical solutions." — Brandon Masterson, 2Morrow, Inc.

Read article…

Previous
Previous

2Morrow Receives the 2019 Best of Kirkland Award in the Software Company Category by the Kirkland Award Program.

Next
Next

TechCrunch: Risks and Rewards of Digital Therapeutics in Treating Mental Disorders